Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorLembo, Maria
dc.contributor.authorJoshi, Shruti Shree
dc.contributor.authorGeers, Jolien
dc.contributor.authorBing, Rong
dc.contributor.authorCarnevale, Lorenzo
dc.contributor.authorPawade, Tania A.
dc.contributor.authorGuala, Andrea
dc.contributor.authorRodríguez Palomares, José F
dc.contributor.authorRuiz Muñoz, Aroa
dc.contributor.authorDux-Santoy Hurtado, Lydia
dc.contributor.authorTeixido-Tura, Gisela
dc.contributor.authorGalian-Gay, Laura
dc.date.accessioned2024-11-14T08:48:52Z
dc.date.available2024-11-14T08:48:52Z
dc.date.issued2024-11
dc.identifier.citationLembo M, Joshi SS, Geers J, Bing R, Carnevale L, Pawade TA, et al. Quantitative Computed Tomography Angiography for the Evaluation of Valvular Fibrocalcific Volume in Aortic Stenosis. JACC Cardiovasc Imaging. 2024 Nov;17(11):1351–62.
dc.identifier.issn1936-878X
dc.identifier.urihttps://hdl.handle.net/11351/12222
dc.descriptionAortic valve stenosis; Fibrocalcific volume; Gaussian mixture model
dc.description.abstractBackground Aortic stenosis (AS) is characterized by calcification and fibrosis. The ability to quantify these processes simultaneously has been limited with previous imaging methods. Objectives The purpose of this study was to evaluate the aortic valve fibrocalcific volume by computed tomography (CT) angiography in patients with AS, in particular, to assess its reproducibility, association with histology and disease severity, and ability to predict/track progression. Methods In 136 patients with AS, fibrocalcific volume was calculated on CT angiograms at baseline and after 1 year. CT attenuation distributions were analyzed using Gaussian-mixture-modeling to derive thresholds for tissue types enabling the quantification of calcific, noncalcific, and fibrocalcific volumes. Scan-rescan reproducibility was assessed and validation provided against histology and in an external cohort. Results Fibrocalcific volume measurements took 5.8 ± 1.0 min/scan, demonstrating good correlation with ex vivo valve weight (r = 0.51; P < 0.001) and excellent scan-rescan reproducibility (mean difference −1%, limits of agreement −4.5% to 2.8%). Baseline fibrocalcific volumes correlated with mean gradient on echocardiography in both male and female participants (rho = 0.64 and 0.69, respectively; both P < 0.001) and in the external validation cohort (n = 66, rho = 0.58; P < 0.001). The relationship was driven principally by calcific volume in men and fibrotic volume in women. After 1 year, fibrocalcific volume increased by 17% and correlated with progression in mean gradient (rho = 0.32; P = 0.003). Baseline fibrocalcific volume was the strongest predictor of subsequent mean gradient progression, with a particularly strong association in female patients (rho = 0.75; P < 0.001). Conclusions The aortic valve fibrocalcific volume provides an anatomic assessment of AS severity that can track disease progression precisely. It correlates with disease severity and hemodynamic progression in both male and female patients.
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesJACC: Cardiovascular Imaging;17(11)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectFibrosi
dc.subjectCalci - Metabolisme - Trastorns
dc.subjectAngiografia
dc.subjectVàlvula aòrtica - Estenosi - Imatgeria
dc.subject.meshAortic Valve Stenosis
dc.subject.mesh/diagnostic imaging
dc.subject.meshComputed Tomography Angiography
dc.subject.meshCalcinosis
dc.subject.meshFibrosis
dc.titleQuantitative Computed Tomography Angiography for the Evaluation of Valvular Fibrocalcific Volume in Aortic Stenosis
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.jcmg.2024.06.007
dc.subject.decsestenosis de la válvula aórtica
dc.subject.decs/diagnóstico por imagen
dc.subject.decsangiografía por tomografía computarizada
dc.subject.decscalcinosis
dc.subject.decsfibrosis
dc.relation.publishversionhttps://doi.org/10.1016/j.jcmg.2024.06.007
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Lembo M] Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy. [Joshi SS, Bing R, Pawade TA] BHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom. [Geers J] BHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom. Department of Cardiology, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), Brussels, Belgium. [Carnevale L] Department of AngioCardioNeurology and Translational Medicine, IRCCS Neuromed, Pozzilli, Italy. [Guala A] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. CIBER-CV, Instituto de Salud Carlos III, Madrid, Spain. [Rodriguez-Palomares JF] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. CIBER-CV, Instituto de Salud Carlos III, Madrid, Spain. Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Ruiz-Muñoz A] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Dux-Santoy L] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Teixido-Tura G] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Galian-Gay L] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain
dc.identifier.pmid39115499
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record